Summary & Overview
HCPCS Level II J9118: Injection of calaspargase pegol-mknl, 10 units
HCPCS Level II code J9118 denotes the injection of calaspargase pegol-mknl, billed per 10-unit increment. This oncology biologic is administered parenterally and is relevant to hospital outpatient departments, infusion centers, and physician offices that provide chemotherapy and related supportive care. Nationally, accurate coding of such high-cost injectable agents affects clinical billing, patient cost-sharing, and payer authorization workflows.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, payer coverage considerations, and the clinical context for use. The publication highlights benchmarks and billing practice patterns where available, summarizes relevant policy and reimbursement considerations, and outlines typical service lines and sites of care associated with administration of calaspargase pegol-mknl.
The report is intended for medical coders, revenue cycle staff, oncology clinicians, and policy analysts seeking a clear reference on coding, billing sites of service, and payer landscape for J9118. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code J9118 describes an injection of calaspargase pegol-mknl, billed in increments of 10 units. This product is an oncology biologic formulation used in the treatment of certain hematologic malignancies and is administered parenterally.
Service Type: Drug administration (parenteral oncology infusion/injection)
Typical Site of Service: Outpatient hospital infusion center, physician office, or outpatient clinic
Clinical & Coding Specifications
Clinical Context
A typical patient is a pediatric or young adult with acute lymphoblastic leukemia (ALL) requiring enzyme-targeted chemotherapy. The patient presents to an outpatient oncology infusion clinic for scheduled intravenous administration of J9118 (calaspargase pegol-mknl) dosed per institutional protocol. Prior to infusion, nursing confirms current weight, obtains baseline vital signs and hepatic panel, reviews coagulation studies, checks for prior hypersensitivity to pegylated asparaginase products, and verifies premedications as ordered. The pharmacy compounds the dose and performs independent dose verification. During infusion, the nurse monitors for infusion reactions, pancreatitis signs, bleeding, and thrombosis. Post-infusion observation includes monitoring vitals and documenting administered units, lot number, and any adverse events in the medical record. Billing occurs under HCPCS Level II code J9118 with the appropriate unit quantity reported and any applicable modifier for coverage or payment circumstances.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered | When part of a single-use vial is wasted and payer requires reporting of discarded drug |